AVEO Pharma (AVEO) to Present Data from Tivozanib at AACR 12

Article Stock Quotes (1) Comments (0)

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and preclinical data on AV-203, AVEO’s ErbB3 inhibitory antibody, will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31-April 4, 2012 in Chicago.

For the schedule, click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Depomed (DEPO) Reports Submission of ANDA for Generic Zipsor
• Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero Over Rapaflo Patent
• Pluristem (PSTI) Updates on IC Progress; German Trial Now on Hold

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?